Low-intensity venetoclax-based preconditioning followed by sequential alloSCT for R/R AML or HR-MDS 

Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses a study that aimed to evaluate the efficacy and safety of venetoclax-based preconditioning followed by sequential allogeneic stem cell transplantation (alloSCT) for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS) treated in the real-world setting. The majority of patients achieved complete remission (CR) with this therapeutic approach, and overall survival (OS) and progression-free survival (PFS) data were promising. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.